{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:17:44Z","timestamp":1785295064413,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was funded by the National Key R&D Program of China","award":["No.2018YFA0900804"],"award-info":[{"award-number":["No.2018YFA0900804"]}]},{"name":"the Key scientific research projects of colleges and universities in Henan Province","award":["21A530001"],"award-info":[{"award-number":["21A530001"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.22108100"],"award-info":[{"award-number":["No.22108100"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Jiangsu Province","award":["BK20210472"],"award-info":[{"award-number":["BK20210472"]}]},{"name":"the national first-class discipline program of Light Industry Technology and Engineering","award":["LITE2018-24"],"award-info":[{"award-number":["LITE2018-24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AMB Expr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Herpes zoster is caused by reactivation of the varicella zoster virus (VZV). Researching and developing a herpes zoster vaccine will help to decrease the incidence of herpes zoster. To increase the bioreactor productivity, a serum-free HEK293 cell perfusion process with adenovirus vector herpes zoster (rAd-HZ) vaccine production was developed efficiently using the design of experiment (DoE) method. First, serum-free media for HEK293 cells were screened in both batch and semi-perfusion culture modes. Then, three optimal media were employed in a medium mixture design to improve cell culture performance, and the 1:1 mixture of HEK293 medium and MCD293 medium (named HM293 medium) was identified as the optimal formulation. On the basis of the HM293 medium, the relationship of critical process parameters (CPPs), including the time of infection (TOI), multiplicity of infection (MOI), pH, and critical quality attributes (CQAs) (adenovirus titer (Titer), cell-specific virus yield (CSVY), adenovirus fold expansion (Fold)) of rAd-HZ production was investigated using the DoE approach. Furthermore, the robust setpoint and design space of these CPPs were explored. Finally, the rAd-HZ production process with parameters at a robust setpoint (TOI\u2009=\u20097.2\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> cells\/mL, MOI\u2009=\u20093.7, and pH\u2009=\u20097.17) was successfully scaled-up to a 3-L bioreactor with an alternating tangential flow system, yielding an adenovirus titer of 3.0\u2009\u00d7\u200910<jats:sup>10<\/jats:sup> IFU\/mL, a CSVY of 4167 IFU\/cells, a Fold of 1117 at 2 days post infection (dpi). The DoE approach accelerated the development of a HEK293 serum-free medium and of a robust adenovirus production process.<\/jats:p>","DOI":"10.1186\/s13568-022-01398-7","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T13:03:34Z","timestamp":1652533414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production"],"prefix":"10.1186","volume":"12","author":[{"given":"Yang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqi","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"issue":"3","key":"1398_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00253-005-1980-8","volume":"68","author":"M Butler","year":"2005","unstructured":"Butler M (2005) Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol 68(3):283\u2013291. https:\/\/doi.org\/10.1007\/s00253-005-1980-8","journal-title":"Appl Microbiol Biotechnol"},{"issue":"5","key":"1398_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/biot.201400429","volume":"10","author":"T Frensing","year":"2015","unstructured":"Frensing T (2015) Defective interfering viruses and their impact on vaccines and viral vectors. Biotechnol J 10(5):681\u2013689. https:\/\/doi.org\/10.1002\/biot.201400429","journal-title":"Biotechnol J"},{"issue":"44","key":"1398_CR3","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.1016\/j.vaccine.2019.09.044","volume":"37","author":"JF Gelinas","year":"2019","unstructured":"Gelinas JF, Azizi H, Kiesslich S, Lanthier S, Perdersen J, Chahal PS, Ansorge S, Kobinger G, Gilbert R, Kamen AA (2019) Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells. Vaccine 37(44):6624\u20136632. https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.044","journal-title":"Vaccine"},{"issue":"4","key":"1398_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s12052-011-0365-y","volume":"4","author":"KA Hanley","year":"2011","unstructured":"Hanley KA (2011) The double-edged sword: How evolution can make or break a live-attenuated virus vaccine. Evol 4(4):635\u2013643. https:\/\/doi.org\/10.1007\/s12052-011-0365-y","journal-title":"Evol"},{"issue":"12 Suppl 2","key":"1398_CR5","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","volume":"224","author":"R Harbecke","year":"2021","unstructured":"Harbecke R, Cohen JI, Oxman MN (2021) Herpes zoster vaccines. J Infect Dis 224(12 Suppl 2):S429\u2013S442. https:\/\/doi.org\/10.1093\/infdis\/jiab387","journal-title":"J Infect Dis"},{"issue":"8","key":"1398_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/14760584.2019.1646129","volume":"18","author":"R Harpaz","year":"2019","unstructured":"Harpaz R (2019) Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States. Expert Rev Vaccines 18(8):793\u2013811. https:\/\/doi.org\/10.1080\/14760584.2019.1646129","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"1398_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3344\/kjp.2015.28.3.177","volume":"28","author":"YH Jeon","year":"2015","unstructured":"Jeon YH (2015) Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain 28(3):177\u2013184. https:\/\/doi.org\/10.3344\/kjp.2015.28.3.177","journal-title":"Korean J Pain"},{"issue":"1","key":"1398_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10616-012-9462-1","volume":"65","author":"M Jordan","year":"2013","unstructured":"Jordan M, Voisard D, Berthoud A, Tercier L, Kleuser B, Baer G, Broly H (2013) Cell culture medium improvement by rigorous shuffling of components using media blending. Cytotechnology 65(1):31\u201340. https:\/\/doi.org\/10.1007\/s10616-012-9462-1","journal-title":"Cytotechnology"},{"issue":"5","key":"1398_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/biot.201400390","volume":"10","author":"H Kallel","year":"2015","unstructured":"Kallel H, Kamen AA (2015) Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials. Biotechnol J 10(5):741\u2013747. https:\/\/doi.org\/10.1002\/biot.201400390","journal-title":"Biotechnol J"},{"issue":"Suppl 1","key":"1398_CR10","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1002\/jgm.503","volume":"6","author":"A Kamen","year":"2004","unstructured":"Kamen A, Henry O (2004) Development and optimization of an adenovirus production process. J Gene Med 6(Suppl 1):S184\u2013192. https:\/\/doi.org\/10.1002\/jgm.503","journal-title":"J Gene Med"},{"key":"1398_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10616-021-00468-1","author":"KS Kim","year":"2021","unstructured":"Kim KS, Park SA, Wui SR, Ko A, Lee NG (2021) Culture media optimization for Chinese hamster ovary cell growth and expression of recombinant varicella-zoster virus glycoprotein E. Cytotechnology. https:\/\/doi.org\/10.1007\/s10616-021-00468-1","journal-title":"Cytotechnology"},{"issue":"22","key":"1398_CR12","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC, Group ZOES (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372(22):2087\u20132096. https:\/\/doi.org\/10.1056\/NEJMoa1501184","journal-title":"N Engl J Med"},{"key":"1398_CR13","doi-asserted-by":"publisher","first-page":"646363","DOI":"10.3389\/fbioe.2021.646363","volume":"9","author":"W Li","year":"2021","unstructured":"Li W, Fan Z, Lin Y, Wang TY (2021) Serum-free medium for recombinant protein expression in chinese hamster ovary cells. Front Bioeng Biotechnol 9:646363. https:\/\/doi.org\/10.3389\/fbioe.2021.646363","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"1398_CR14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/btpr.2472","volume":"33","author":"H Lin","year":"2017","unstructured":"Lin H, Leighty RW, Godfrey S, Wang SB (2017) Principles and approach to developing mammalian cell culture media for high cell density perfusion process leveraging established fed-batch media. Biotechnol Prog 33(4):891\u2013901. https:\/\/doi.org\/10.1002\/btpr.2472","journal-title":"Biotechnol Prog"},{"issue":"10255","key":"1398_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 396(10255):887\u2013897. https:\/\/doi.org\/10.1016\/S0140-6736(20)31866-3","journal-title":"Lancet"},{"issue":"4","key":"1398_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/hum.2013.235","volume":"25","author":"D Majhen","year":"2014","unstructured":"Majhen D, Calderon H, Chandra N, Fajardo CA, Rajan A, Alemany R, Custers J (2014) Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther 25(4):301\u2013317. https:\/\/doi.org\/10.1089\/hum.2013.235","journal-title":"Hum Gene Ther"},{"key":"1398_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","volume":"479","author":"PD Minor","year":"2015","unstructured":"Minor PD (2015) Live attenuated vaccines: Historical successes and current challenges. Virology 479:379\u2013392. https:\/\/doi.org\/10.1016\/j.virol.2015.03.032","journal-title":"Virology"},{"issue":"2","key":"1398_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ymben.2011.12.006","volume":"14","author":"BC Mulukutla","year":"2012","unstructured":"Mulukutla BC, Gramer M, Hu WS (2012) On metabolic shift to lactate consumption in fed-batch culture of mammalian cells. Metab Eng 14(2):138\u2013149. https:\/\/doi.org\/10.1016\/j.ymben.2011.12.006","journal-title":"Metab Eng"},{"key":"1398_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fimmu.2014.00005","volume":"5","author":"K Nieto","year":"2014","unstructured":"Nieto K, Salvetti A (2014) AAV vectors vaccines against infectious diseases. Front Immunol 5:5. https:\/\/doi.org\/10.3389\/fimmu.2014.00005","journal-title":"Front Immunol"},{"issue":"22","key":"1398_CR20","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1016\/j.vaccine.2017.04.086","volume":"36","author":"A Patel","year":"2018","unstructured":"Patel A, Erb SM, Strange L, Shukla RS, Kumru OS, Smith L, Nelson P, Joshi SB, Livengood JA, Volkin DB (2018) Combined semi-empirical screening and design of experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate. Vaccine 36(22):3169\u20133179. https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.086","journal-title":"Vaccine"},{"issue":"3","key":"1398_CR21","doi-asserted-by":"publisher","first-page":"e1700499","DOI":"10.1002\/biot.201700499","volume":"13","author":"S Pereira","year":"2018","unstructured":"Pereira S, Kildegaard HF, Andersen MR (2018) Impact of CHO metabolism on cell growth and protein production: an overview of toxic and Inhibiting metabolites and nutrients. Biotechnol J 13(3):e1700499. https:\/\/doi.org\/10.1002\/biot.201700499","journal-title":"Biotechnol J"},{"key":"1398_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41541-020-00228-w","volume":"5","author":"D Poncet","year":"2020","unstructured":"Poncet D, Hessler C, Liang H, Gautheron S, Sergent M, Rintala ND, Seydoux E, Huang PD, Argilla D, Ruiz S, Heinrichs J, Maciel M Jr, Orr MT (2020) Preclinical optimization of an enterotoxigenic Escherichia coli adjuvanted subunit vaccine using response surface design of experiments. NPJ Vaccines 5:83. https:\/\/doi.org\/10.1038\/s41541-020-00228-w","journal-title":"NPJ Vaccines"},{"issue":"3","key":"1398_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4103\/2230-973X.187350","volume":"6","author":"K Pramod","year":"2016","unstructured":"Pramod K, Tahir MA, Charoo NA, Ansari SH, Ali J (2016) Pharmaceutical product development: A quality by design approach. Int J Pharm Investig 6(3):129\u2013138. https:\/\/doi.org\/10.4103\/2230-973X.187350","journal-title":"Int J Pharm Investig"},{"issue":"4","key":"1398_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12010-012-0068-z","volume":"169","author":"ME Rodrigues","year":"2013","unstructured":"Rodrigues ME, Costa AR, Henriques M, Cunnah P, Melton DW, Azeredo J, Oliveira R (2013) Advances and drawbacks of the adaptation to serum-free culture of CHO-K1 cells for monoclonal antibody production. Appl Biochem Biotechnol 169(4):1279\u20131291. https:\/\/doi.org\/10.1007\/s12010-012-0068-z","journal-title":"Appl Biochem Biotechnol"},{"issue":"3","key":"1398_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4161\/mabs.23942","volume":"5","author":"Y Rouiller","year":"2013","unstructured":"Rouiller Y, Perilleux A, Collet N, Jordan M, Stettler M, Broly H (2013) A high-throughput media design approach for high performance mammalian fed-batch cultures. MAbs 5(3):501\u2013511. https:\/\/doi.org\/10.4161\/mabs.23942","journal-title":"MAbs"},{"key":"1398_CR26","doi-asserted-by":"publisher","first-page":"100432","DOI":"10.1016\/j.dmpk.2021.100432","volume":"42","author":"F Sakurai","year":"2022","unstructured":"Sakurai F, Tachibana M, Mizuguchi H (2022) Adenovirus vector-based vaccine for infectious diseases. Drug Metab Pharmacokinet 42:100432. https:\/\/doi.org\/10.1016\/j.dmpk.2021.100432","journal-title":"Drug Metab Pharmacokinet"},{"key":"1398_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jbiotec.2019.12.017","volume":"309","author":"H Schwarz","year":"2020","unstructured":"Schwarz H, Zhang Y, Zhan C, Malm M, Field R, Turner R, Sellick C, Varley P, Rockberg J, Chotteau V (2020) Small-scale bioreactor supports high density HEK293 cell perfusion culture for the production of recombinant Erythropoietin. J Biotechnol 309:44\u201352. https:\/\/doi.org\/10.1016\/j.jbiotec.2019.12.017","journal-title":"J Biotechnol"},{"issue":"29","key":"1398_CR28","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1016\/j.vaccine.2016.04.090","volume":"34","author":"CF Shen","year":"2016","unstructured":"Shen CF, Jacob D, Zhu T, Bernier A, Shao Z, Yu X, Patel M, Lanthier S, Kamen A (2016) Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate. Vaccine 34(29):3381\u20133387. https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.090","journal-title":"Vaccine"},{"issue":"2","key":"1398_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0168-1656(95)00153-0","volume":"45","author":"TS Stoll","year":"1996","unstructured":"Stoll TS, Muhlethaler K, von Stockar U (1996) Systematic improvement of a chemically-defined protein-free medium for hybridoma growth and monoclonal antibody production. J Biotechnol 45(2):111\u2013123. https:\/\/doi.org\/10.1016\/0168-1656(95)00153-0","journal-title":"J Biotechnol"},{"issue":"5","key":"1398_CR30","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00253-015-7267-9","volume":"100","author":"F Tapia","year":"2016","unstructured":"Tapia F, Vazquez-Ramirez D, Genzel Y, Reichl U (2016) Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production. Appl Microbiol Biotechnol 100(5):2121\u20132132. https:\/\/doi.org\/10.1007\/s00253-015-7267-9","journal-title":"Appl Microbiol Biotechnol"},{"issue":"4","key":"1398_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.biologicals.2007.02.002","volume":"35","author":"H Toriniwa","year":"2007","unstructured":"Toriniwa H, Komiya T (2007) Japanese encephalitis virus production in Vero cells with serum-free medium using a novel oscillating bioreactor. Biologicals 35(4):221\u2013226. https:\/\/doi.org\/10.1016\/j.biologicals.2007.02.002","journal-title":"Biologicals"},{"issue":"1","key":"1398_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tiv.2003.08.009","volume":"18","author":"J van der Valk","year":"2004","unstructured":"van der Valk J, Mellor D, Brands R, Fischer R, Gruber F, Gstraunthaler G, Hellebrekers L, Hyllner J, Jonker FH, Prieto P, Thalen M, Baumans V (2004) The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicol In Vitro 18(1):1\u201312. https:\/\/doi.org\/10.1016\/j.tiv.2003.08.009","journal-title":"Toxicol In Vitro"},{"issue":"6 Suppl","key":"1398_CR33","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.jaad.2007.08.046","volume":"57","author":"JM Weinberg","year":"2007","unstructured":"Weinberg JM (2007) Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol 57(6 Suppl):S130\u2013135. https:\/\/doi.org\/10.1016\/j.jaad.2007.08.046","journal-title":"J Am Acad Dermatol"},{"issue":"suppl2","key":"1398_CR34","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/infdis\/jiy383","volume":"218","author":"A Weinberg","year":"2018","unstructured":"Weinberg A, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Levin MJ (2018) Comparative immune responses to licensed herpes zoster vaccines. J Infect Dis 218(suppl2):S81\u2013S87. https:\/\/doi.org\/10.1093\/infdis\/jiy383","journal-title":"J Infect Dis"},{"issue":"4","key":"1398_CR35","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00253-020-11050-8","volume":"105","author":"Y Wu","year":"2021","unstructured":"Wu Y, Bissinger T, Genzel Y, Liu X, Reichl U, Tan WS (2021) High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells. Appl Microbiol Biotechnol 105(4):1421\u20131434. https:\/\/doi.org\/10.1007\/s00253-020-11050-8","journal-title":"Appl Microbiol Biotechnol"},{"issue":"5","key":"1398_CR36","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/21645515.2015.1016674","volume":"11","author":"K Xiang","year":"2015","unstructured":"Xiang K, Ying G, Yan Z, Shanshan Y, Lei Z, Hongjun L, Maosheng S (2015) Progress on adenovirus-vectored universal influenza vaccines. Hum Vaccin Immunother 11(5):1209\u20131222. https:\/\/doi.org\/10.1080\/21645515.2015.1016674","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"1398_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/rmb2.12024","volume":"16","author":"T Yao","year":"2017","unstructured":"Yao T, Asayama Y (2017) Animal-cell culture media: History, characteristics, and current issues. Reprod Med Biol 16(2):99\u2013117. https:\/\/doi.org\/10.1002\/rmb2.12024","journal-title":"Reprod Med Biol"},{"issue":"1","key":"1398_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajps.2016.07.006","volume":"12","author":"L Zhang","year":"2017","unstructured":"Zhang L, Mao S (2017) Application of quality by design in the current drug development. Asian J Pharm Sci 12(1):1\u20138. https:\/\/doi.org\/10.1016\/j.ajps.2016.07.006","journal-title":"Asian J Pharm Sci"},{"issue":"10240","key":"1398_CR39","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/s0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W (2020) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395(10240):1845\u20131854. https:\/\/doi.org\/10.1016\/s0140-6736(20)31208-3","journal-title":"Lancet"}],"container-title":["AMB Express"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13568-022-01398-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13568-022-01398-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13568-022-01398-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T13:24:31Z","timestamp":1652534671000},"score":1,"resource":{"primary":{"URL":"https:\/\/amb-express.springeropen.com\/articles\/10.1186\/s13568-022-01398-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1186\/s13568-022-01398-7","relation":{},"ISSN":["2191-0855"],"issn-type":[{"value":"2191-0855","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"58"}}